Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 413-418

  Staines, Donald R ^a  

^a Gold Coast Public Health Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; NEUROPEPTIDE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL DEATH; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; GLIA CELL; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, G-PROTEIN-COUPLED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 37448999541     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.038     Document Type: Article

References (69)

1. Staines D.R. Postulated vasoactive neuropeptide autoimmunity in fatigue-related conditions: a brief review and hypothesis. Clin Devel Immunol 13 1 (2006) 25-39
2. Martin B., Lopez de Maturana R., Brenneman R., Walent T., Mattson M.P., and Maudsley S. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med 7 1-2 (2005) 3-36
3. Simpson C.L., and Al-Chalabi A. Amyotrophic lateral sclerosis as a complex genetic disease. Biochim Biophys Acta 1762 11-12 (2006) 973-985
4. Morahan J.M., and Pamphlett R. Amyotrophic lateral sclerosis and exposure to environmental toxins: an Australian case-control study. Neuroepidemiology 27 3 (2006) 130-135
5. Rose M.R., and Brix K.A. Neurological disorders in Gulf War veterans. Philos Trans R Soc Lond B Biol Sci 361 1468 (2006) 605-618
6. Capparos-Lefebvre D., Steele J., Kotake Y., and Ohta S. Geographic isolates of atypical Parkinsonism and tauopathy in the tropics: possible synergy of neurotoxins. Mov Disord 21 10 (2006) 1769-1771
7. Banack S.A., and Cox P.A. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology 61 3 (2003) 387-389
8. Wang G., Qi C., Fan G.H., Zhou H.Y., and Chen S.D. PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex 1 inhibitor, rotenone. FEBS Lett 579 18 (2005) 4005-4011
9. Reglodi D., Lubics A., Kiss P., Lengvari I., Gaszner B., Toth G., et al. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats. Neuropeptides 40 4 (2006) 265-274
10. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part 1: The role of infection. Ann Neurol 61 4 (2007) 288-299
11. Spach K.M., Nashfold F.E., Dittel B.N., and Hayes C.E. IL-10 signalling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 177 9 (2006) 6030-6037
12. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162 3 (1999) 1707-1716
13. Murphy J., Henry R., and Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 64 3 (2007) 330-334
14. Rippon G.A., Scarmeas N., Gordon P.H., Murphy P.L., Albert S.M., Mitsumoto H., et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 63 3 (2006) 345-352
15. Grossman A.B., Wooley-Levine S., Bradley W.G., and Miller R.G. Detecting neurobehavioral changes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 8 1 (2007) 56-61
16. Pinkhardt E.H., van Elst L.T., Ludolph A.C., and Kassubek J. Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry. BMC Neurol 6 (2006) 48
17. Stanton BR, Williams VC, Leigh PN, Williams SC, Blain CR, Jarosz JM, et al. Altered cortical activation during a motor task in ALS: evidence for involvement of central pathways. J Neurol Mar 25, 2007 [Epub ahead of print].
18. Kalra S., Vitale A., Cashman N.R., Genge A., and Arnold D.L. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 77 11 (2006) 1253-1255
19. Rendell P.G., Jensen F., and Henry J.D. Prospective memory in multiple sclerosis. J Int Neuropsychol Soc 13 3 (2007) 410-416
20. Parmenter B.A., Shucard J.L., and Shucard D.W. Information processing deficits in multiple sclerosis: a matter of complexity. J Int Neuropsychol Soc 13 3 (2007) 417-423
21. Argaw A.T., Zhang Y., Snyder B.J., Zhao M.L., Kopp N., Lee S.C., et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 177 8 (2006) 5574-5584
22. Chi O.Z., Hunter C., Liu X., and Weiss H.R. Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. Exp Neurol 204 1 (2007) 283-287
23. Nygren I., Larsson A., Johansson A., and Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport 13 17 (2002) 2199-2201
24. Kira J. Multiple sclerosis. Rinsho Shinkeigaku 45 11 (2005) 912-915
25. Chung Y.H., Joo K.M., Kim Y.S., Lee K.H., Lee W.B., and Cha C.I. Enhanced expression of erythropoietin in the central nervous system of SOD1(G93A) transgenic mice. Brain Res 1016 2 (2004) 272-280
26. Just N., Moreau C., Lasalle P., Gosset P., Perez T., Brunaud-Danel V., et al. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxic ALS patients suggest an abnormal response to hypoxia. Neuromusc Disord 17 2 (2007) 169-173
27. Brettschneider J., Widl K., Schattauer D., Ludolph A.C., and Tumani H. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci Lett 416 3 (2007) 257-260
28. Graumann U., Reynolds R., Steck A.J., and Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13 4 (2003) 554-573
29. Aboul-Enein F., and Lassman H. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease?. Acta Neuropathol 109 1 (2005) 49-55
30. Vaudry D., Hamelink C., Damadzic R., Eskay R.L., Gonzalez B., and Eiden L.E. Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 26 12 (2005) 2518-2524
31. Dhib-Jalbut S., Arnold D.L., Cleveland D.W., Fisher M., Friedlander R.M., Mouradian M.M., et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 176 1-2 (2006) 198-215
32. Okada K., Yamashita U., and Tsuji S. Modulation of Na(+)-dependent glutamate transporter of murine astrocytes by inflammatory mediators. J UOEH 27 2 (2005) 161-170
33. Ferri A., Nencini M., Casciati A., Cozzolino M., Angelini D.F., Longone P., et al. Cell death in amyotrophic lateral sclerosis: interplay between neuronal and glial cells. FASEB J 18 11 (2004) 1261-1263
34. Norenberg MD, Rao KV. The mitochondrial permeability transition in neurologic disease. Neurochem Int Mar 4, 2007 [Epub ahead in print].
35. Tokuda E, Ono SI, Ishige K, Watanabe S, Okawa E, Ito Y, et al. Dysequilibrium between caspases and their inhibitors in a mouse model for amyotrophic lateral sclerosis. Brain Res Mar 7, 2007 [Epub ahead of print].
36. Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., Giorgini A., et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci 23 2 (2003) 180-192
37. Wilkins A., and Compston A. Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen-activated protein kinase signalling pathways. J Neurochem 92 6 (2005) 1487-1496
38. Veglianese P., Lo Coco D., Bao Cutrona M., Magnoni R., Pennacchini D., Pozzi B., et al. Activation of the p38MAPK cascade is associated with upregulation of the TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci 31 2 (2006) 218-231
39. Mhatre M., Floyd R.A., and Hensley K. Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimer's Dis 6 2 (2004) 147-157
40. Suk K., Park J.H., and Lee W.H. Neuropeptide PACAP inhibits hypoxic activation of brain microglia: a protective mechanism against microglial neurotoxicity in ischemia. Brain Res 1026 1 (2004) 151-156
41. Racz B, Gasz B, Borsiczky B, Gallyas Jr F, Tamas A, Jozsa R, et al. Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol Dec 27, 2006 [Epub ahead of print].
42. Nguyen M.D., D'Aigle T., Gowing G., Julien J.P., and Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 24 6 (2004) 1340-1349
43. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55 2 (2004) 221-235
44. Hensely K., Fedynyshyn J., Ferrell S., Floyd R.A., Gordon B., Grammas B., et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14 1 (2003) 74-80
45. Ilzecka J., Stelmasiak Z., and Dobosz B. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 20 5 (2002) 239-243
46. Houi K., Kobayashi T., Kato S., Mochio S., and Inoue K. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 106 5 (2002) 299-301
47. Kato H., Ito A., Kawanokuchi J., Jin S., Mizuno T., Ojika K., et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 10 6 (2004) 651-659
48. Van Au Duong M, Audoin B, Le Fur Y, Confort-Gouny S, Malikova I, Soulier E, et al. Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study. J Neurol Apr 20, 2007 [Epub ahead of print].
49. Niessen H.G., Debska-Vielhaber G., Sander K., Angenstein F., Ludolph A.C., Hilfert L., et al. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 25 6 (2007) 1669-1677
50. Chen S., and Brown I.R. Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones 12 1 (2007) 51-58
51. Staines D.R. Do vasoactive neuropeptides and heat shock proteins mediate fatigue-related autoimmune disorders?. Med Hypotheses 64 3 (2005) 539-542
52. Werdelin L., Gjerris A., Boysen G., Fahrenkrug J., Jorgensen O.S., and Rehfeld J.F. Neuropeptides and neural cell adhesion molecule (NCAM) in CSF from patients with ALS. Acta Neurol Scand 79 3 (1989) 177-181
53. Iwasaki Y., Ikeda K., Ichikawa Y., and Igarashi O. Vasoactive intestinal peptide influences neurite outgrowth in cultured rat spinal cord neurons. Neurol Res 23 8 (2001) 851-854
54. Sun W., Hong J., Zang Y.C., Liu X., and Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 18 12 (2006) 1691-1700
55. Barnett M.H., and Sutton I. The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 19 3 (2006) 242-247
56. Jeanneteau F., and Chao M.V. Promoting neurotrophic effects by GPCR ligands. Novartis Found Symp 276 (2006) 181-189
57. Peterssen L.M., Heine T., Verge V.M., Sundler F., and Danielsen N. PACAP mRNA is expressed in rat spinal cord neurons. J Comp Neurol 471 1 (2004) 85-96
58. Fernandez-Martin A., Gonzalez-Rey E., Chorney A., Martin J., Pozo D., Ganea D., et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann N Y Acad Sci 1070 (2006) 276-281
59. Nakamizo T., Kawamata J., Yoshida K., Kawai Y., Kanki R., Sawada H., et al. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res 71 4 (2003) 485-495
60. Giembycz M.A., and Smith S.J. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?. Curr Pharm Des 12 25 (2006) 3207-3220
61. Zhang B., Yang L., Konishi Y., Maeda N., Sakanaka M., and Tanaka J. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP elevating agents. Neuropharmacology 42 2 (2002) 262-269
62. Staines D.R. Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders. Med Hypotheses 66 1 (2006) 203-204
63. Porcel J., and Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J Neurol Sci 245 1-2 (2006) 177-181
64. D'Intino G., Paradisi M., Fernandez M., Giuliani A., Aloe L., Giardino L., et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci 102 8 (2005) 3070-3075
65. Staines D.R. Therapeutic and preventive interventions for postulated vasoactive neuropeptide autoimmune fatigue-related disorders. Med Hypotheses 65 4 (2005) 797-803
66. Ryu H., and Ferrante R.J. Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem 7 2 (2007) 141-150
67. Aguilar JL, Echaniz-Laguna A, Fergani A, Rene F, Meininger V, Loeffler JP, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem Jan 22, 2007 [Epub ahead of print].
68. Cabanes C., Bonilla S., Tabares L., and Martinez S. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis 26 2 (2007) 408-418
69. Fazekas F, Strasser-Fuchs S, Hommes OR. Intravenous immunoglobulin in MS: promise or failure? J Neurol Sci. Apr 19, 2007 [Epub ahead of print].